<DOC>
	<DOCNO>NCT03040934</DOCNO>
	<brief_summary>This study prospective , multi-center , open-label , randomize control clinical trial , aim assess safety effectiveness Firehawk™ sirolimus target-eluting coronary stent system abluminal groove contain biodegradable polymer ( Firehawk™ ) compare XIENCE everolimus-eluting coronary stent system treatment subject total coronary occlusion lesion ( ) .</brief_summary>
	<brief_title>Firehawk™ Coronary Stent System Treatment Total Coronary Artery Occlusion Lesion ( )</brief_title>
	<detailed_description>This study recruit 196 subject total coronary occlusion lesion ( ) coronary artery ≥2.25 mm ≤4.0 mm diameter ≤100 mm length ( visual estimate ) 10 research center China . All participant meet inclusion criterion 1:1 randomize receive Firehawk™ sirolimus target-eluting coronary stent XIENCE everolimus-eluting coronary stent . Optical Coherent Tomography ( OCT ) sub study : first 44 consecutive subject consent participate OCT sub study undergo OCT assessment 3 month 12 month post index procedure . The OCT sub study perform 3-5 pre-selected site . The clinical follow-up carry 30 day , 3 month , 6 month , 12 month , 2-5 year post-index procedure.The primary endpoint in-stent late lumen loss 12 month post-index procedure.The secondary endpoint neo-intimal thickness Optical Coherent Tomography ( OCT ) 3 month post-index procedure .</detailed_description>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Clinical CI1 . Subject must least 18 year age ; CI2 . Subject ( legal guardian ) understand trial requirement treatment procedure provide write informed consent trialspecific test procedure perform ; CI3 . Subject eligible percutaneous coronary intervention ( PCI ) ; CI4 . Subject symptomatic coronary artery disease objective evidence ischemia silent ischemia ; CI5 . Subjects eligible candidate coronary artery bypass graft surgery ( CABG ) ; CI6 . Left ventricular ejection fraction ( LVEF ) within 60 day ≥ 35 % ; Exclusion Criteria ; CI7 . Subject willing comply protocolrequired followup evaluation . Angiographic Inclusion Criteria ( visual estimate ) : AI1 . Target lesion must new visually estimate reference diameter ≥2.25 mm ≤4.0 mm autologous coronary artery ; AI2 . Target lesion must &lt; 100 mm length ( visual estimate ) number implant stent less 4 ; AI3 . Target lesion must visually complete occlusion longer 4 week ; AI4 . Target lesion must able pas successfully expand ; Clinical CE1 . Subjects recently suffer MI ( within 1 week ) , ECG changes/clinical symptom consistent AMI accompany increased cardiac biomarkers ( CKMB , CK , TNT TNI ) exclude ; CE2 . Subjects organ transplant wait organ transplant ; CE3 . Subjects receive chemotherapy receive chemotherapy within 30 day PCI ; CE4 . Subjects undergo chronic ( 72 hour ) anticoagulant therapy ( heparin coumarin ) acute coronary syndrome ; CE5 . Subjects abnormal count platelet white blood cell ( WBC ) : platelet count less 100×10E9/L great 700×10E9/L , white blood cell less 3×10E9/L ; CE6 . Subjects confirm suspect liver disease , include hepatitis lab result ; CE7 . Subjects elevate serum creatinine level &gt; 3.0mg/dL undergoing dialysis therapy ; CE8 . Subjects active peptic ulcer , active gastrointestinal ( GI ) bleed bleed diathesis coagulopathy , refuse blood transfusion ; CE9 . Subjects cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) past 6 month , permanent nerve defect ; CE10 . Subjects PCI ( balloon angioplasty , stent , cut balloon , atherectomy ) treatment target vessel ( include collateral ) within 12 month prior baseline ; CE11 . Subjects plan undergo PCI CABG baseline PCI ; CE12 . Subjects coronary endovascular brachytherapy treatment previously ; CE13 . Subjects associate drug allergy ( sirolimus , structurerelated compound fluorinated polymer , thiophenepyridine aspirin ) ; CE14 . Subjects suffer serious illness ( cancer , congestive heart failure ) , may cause drop life expectancy le 18 month ; CE15 . Subjects currently abuse drug ( alcohol , cocaine , heroin , etc ) ; CE16 . Subject plan undergo operation may lead confuse programme ; CE17 . Subjects participate another study drug medical device meet primary endpoint ; CE18 . Subjects plan pregnant within 18 month baseline ; CE19 . Subjects pregnant breastfeed woman . Angiographic Exclusion Criteria ( visual estimate ) : AE1 . Target lesion follow criterion : left main , saphenous vein graft arterial graft , via saphenous vein graft arterial graft , instent stenosis ; AE2 . Subjects unprotected leave main coronary artery disease ( diameter stenosis &gt; 50 % ) ; AE3 . Subjects protect leave main coronary artery disease ( diameter stenosis &gt; 50 % leave coronary artery bypass surgery ) , well target lesion locate LAD LCX ; AE4 . Subjects lesions clinical significance , may need intervention within 18 month baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>